multiple myeloma; histology
Item
1. must have a histologically confirmed diagnosis of multiple myeloma.
boolean
C0026764 (UMLS CUI [1])
C0019638 (UMLS CUI [2])
age
Item
2. must be >/= 18 years of age.
boolean
C0001779 (UMLS CUI [1])
ecog
Item
3. must have a performance status (ecog ps) of 0-2.
boolean
C1520224 (UMLS CUI [1])
informed consent; lenalidomide
Item
4. must be qualified and have signed consent to receive lenalidomide for maintenance therapy for mm.
boolean
C0021430 (UMLS CUI [1])
C1144149 (UMLS CUI [2])
informed consent
Item
5. must have signed informed consent indicating that they are aware of the investigational nature of the study, and are aware that participation is voluntary.
boolean
C0021430 (UMLS CUI [1])
curcumin self prescribed
Item
6. must also agree to refrain from use of self prescribed curcumin during the course of the study.
boolean
C0010467 (UMLS CUI [1,1])
C0599401 (UMLS CUI [1,2])
pregnancy test negative
Item
7. must have negative pregnancy test before signing consent for mm therapy.
boolean
C0427780 (UMLS CUI [1])
symptom assessment
Item
1. unable to understand the symptom assessment or not willing to participate in the study.
boolean
C3494437 (UMLS CUI [1])
carcinoma; in-situ cervical cancer
Item
2. treatment for other carcinomas within the last 5 years, except for cured non-melanoma skin and treated in-situ cervical cancer.
boolean
C0007097 (UMLS CUI [1])
C0742130 (UMLS CUI [2])
Compliance behavior Limited Comorbidity; antibiotics; cardiac disease
Item
3. uncontrolled intercurrent illness including, but not limited to, ongoing or requiring iv antibiotics, cardiac disease (nyha class iii or iv heart failure), unstable angina pectoris, unstable cardiac arrhythmia or tachycardia, or psychiatric illness/ social situations that would limit compliance with the study requirements are excluded.
boolean
C1321605 (UMLS CUI [1,1])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])
C0003232 (UMLS CUI [2])
C0018799 (UMLS CUI [3])
concurrent medication Coumadin
Item
4. concurrent use of coumadin other than low dose (1 mg) coumadin used for line patency.
boolean
C0205420 (UMLS CUI [1,1])
C0013227 (UMLS CUI [1,2])
C0699129 (UMLS CUI [1,3])
concurrent medication; cimetidine; allopurinol; aluminium hydroxide; magnesium hydroxide; antacids
Item
5. concurrent use of cimetidine, allopurinol, or aluminium hydroxide and magnesium hydroxide-containing antacids such as maalox.
boolean
C0205420 (UMLS CUI [1,1])
C0013227 (UMLS CUI [1,2])
C0008783 (UMLS CUI [2])
C0002144 (UMLS CUI [3])
C0002371 (UMLS CUI [4])
C0024476 (UMLS CUI [5])
C0003138 (UMLS CUI [6])
sorivudine; brivudine
Item
6. sorivudine and brivudine use within 4 weeks of the start of study treatment.
boolean
C0207628 (UMLS CUI [1])
C0163272 (UMLS CUI [2])
gastric ulcers; duodenal ulcers
Item
7. gastric or duodenal ulcers, or gastric hyperacidity disorders.
boolean
C0038358 (UMLS CUI [1])
C0013295 (UMLS CUI [2])
anticoagulants heparin; antiplatelets clopidogrel
Item
8. currently receiving anticoagulants (heparin) or antiplatelets (clopidogrel, ticlopidine, aspirin/dipyridamole)
boolean
C0003280 (UMLS CUI [1,1])
C0019134 (UMLS CUI [1,2])
C0085826 (UMLS CUI [2,1])
C0070166 (UMLS CUI [2,2])
inr
Item
9. inr > 1.5 (upper limit of normal = 1.5).
boolean
C0482691 (UMLS CUI [1])
medical history deep vein thrombosis
Item
10. history of deep vein thrombosis.
boolean
C0262926 (UMLS CUI [1,1])
C0149871 (UMLS CUI [1,2])
allogeneic transplant
Item
11. received allogeneic transplant.
boolean
C0149615 (UMLS CUI [1])
hypersensitivity turmeric; hypersensitivity curcumin
Item
12. allergy to turmeric, curcumin, or yellow dye.
boolean
C0020517 (UMLS CUI [1,1])
C0041356 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0010467 (UMLS CUI [2,2])
bile duct obstruction; bowel obstruction
Item
13. bowel or bile duct obstruction.
boolean
C0008370 (UMLS CUI [1])
C0021843 (UMLS CUI [2])